W David Arnold1, David Kline2, Alan Sanderson2, Ahmed A Hawash2, Amy Bartlett2, Kevin R Novak2, Mark M Rich2, John T Kissel2. 1. From the Department of Neurology (W.D.A., A.S., A.B., J.T.K.), The Ohio State University Wexner Medical Center; Center for Biostatistics (D.K.), Department of Biomedical Informatics, The Ohio State University, Columbus; and Neuroscience, Cell Biology, and Physiology and Neurology (A.A.H., K.R.N., M.M.R.), Wright State University, Dayton, OH. william.arnold@osumc.edu. 2. From the Department of Neurology (W.D.A., A.S., A.B., J.T.K.), The Ohio State University Wexner Medical Center; Center for Biostatistics (D.K.), Department of Biomedical Informatics, The Ohio State University, Columbus; and Neuroscience, Cell Biology, and Physiology and Neurology (A.A.H., K.R.N., M.M.R.), Wright State University, Dayton, OH.
Abstract
OBJECTIVE: To determine open-label, pilot study whether ranolazine could improve signs and symptoms of myotonia and muscle stiffness in patients with myotonia congenita (MC). METHODS: Thirteen participants were assessed at baseline and 2, 4, and 5 weeks. Ranolazine was started after baseline assessment (500 mg twice daily), increased as tolerated after week 2 (1,000 mg twice daily), and maintained until week 4. Outcomes included change from baseline to week 4 in self-reported severity of symptoms (stiffness, weakness, and pain), Timed Up and Go (TUG), hand grip and eyelid myotonia, and myotonia on EMG. RESULTS: Self-reported severity of stiffness (p < 0.0001) and weakness (p < 0.01) was significantly improved compared with baseline. TUG and grip myotonia times were reduced (p = 0.03, p = 0.01). EMG of the abductor digiti minimi and tibialis anterior showed significantly reduced myotonia duration (p < 0.001, p < 0.01) at week 4. No participant discontinued ranolazine because of side effects. CONCLUSIONS: Ranolazine appeared to be well tolerated over a period of 4 weeks in individuals with MC, and ranolazine resulted in improvement of signs and symptoms of muscle stiffness. The findings of this study suggest that ranolazine should be investigated in a larger controlled study. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that ranolazine improves myotonia in myotonia congenita.
OBJECTIVE: To determine open-label, pilot study whether ranolazine could improve signs and symptoms of myotonia and muscle stiffness in patients with myotonia congenita (MC). METHODS: Thirteen participants were assessed at baseline and 2, 4, and 5 weeks. Ranolazine was started after baseline assessment (500 mg twice daily), increased as tolerated after week 2 (1,000 mg twice daily), and maintained until week 4. Outcomes included change from baseline to week 4 in self-reported severity of symptoms (stiffness, weakness, and pain), Timed Up and Go (TUG), hand grip and eyelid myotonia, and myotonia on EMG. RESULTS: Self-reported severity of stiffness (p < 0.0001) and weakness (p < 0.01) was significantly improved compared with baseline. TUG and grip myotonia times were reduced (p = 0.03, p = 0.01). EMG of the abductor digiti minimi and tibialis anterior showed significantly reduced myotonia duration (p < 0.001, p < 0.01) at week 4. No participant discontinued ranolazine because of side effects. CONCLUSIONS:Ranolazine appeared to be well tolerated over a period of 4 weeks in individuals with MC, and ranolazine resulted in improvement of signs and symptoms of muscle stiffness. The findings of this study suggest that ranolazine should be investigated in a larger controlled study. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that ranolazine improves myotonia in myotonia congenita.
Authors: Nesrine El-Bizri; Kristopher M Kahlig; John C Shyrock; Alfred L George; Luiz Belardinelli; Sridharan Rajamani Journal: Channels (Austin) Date: 2011-03-01 Impact factor: 2.581
Authors: Jeffrey M Statland; Brian N Bundy; Yunxia Wang; Dipa Raja Rayan; Jaya R Trivedi; Valeria A Sansone; Mohammad K Salajegheh; Shannon L Venance; Emma Ciafaloni; Emma Matthews; Giovanni Meola; Laura Herbelin; Robert C Griggs; Richard J Barohn; Michael G Hanna Journal: JAMA Date: 2012-10-03 Impact factor: 56.272
Authors: Samantha Lorusso; David Kline; Amy Bartlett; Miriam Freimer; Julie Agriesti; Ahmed A Hawash; Mark M Rich; John T Kissel; W David Arnold Journal: Muscle Nerve Date: 2018-12-21 Impact factor: 3.217
Authors: Bas C Stunnenberg; Samantha LoRusso; W David Arnold; Richard J Barohn; Stephen C Cannon; Bertrand Fontaine; Robert C Griggs; Michael G Hanna; Emma Matthews; Giovanni Meola; Valeria A Sansone; Jaya R Trivedi; Baziel G M van Engelen; Savine Vicart; Jeffrey M Statland Journal: Muscle Nerve Date: 2020-05-27 Impact factor: 3.217